Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight
The epilepsy market is expected to grow due to an increase in disease prevalence and the expected launch of emerging therapies, including Azetukalner (XEN1101; Xenon Pharmaceuticals), ABS-1230 (Actio Biosciences), BHV-7000 (Biohaven Pharmaceuticals), Relutrigine (PRAX-562; Praxis...
Covered in this story
Call it yourself
No calls on $PRAX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Praxis Precision Medicines Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.